Profile for China Patent: 105963834

US Patent Family Members and Approved Drugs for China Patent: 105963834

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
11,419,914	Jun 15, 2030	Acerus Pharms	NOCTIVA	desmopressin acetate
12,090,190	Jun 15, 2030	Acerus Pharms	NOCTIVA	desmopressin acetate
9,539,302	Jun 15, 2030	Acerus Pharms	NOCTIVA	desmopressin acetate

Analysis of Patent CN105963834: Scope, Claims, and Landscape

Last updated: February 20, 2026

What is the scope of patent CN105963834?

Patent CN105963834 covers a composition and method for treating specific diseases, likely within the domain of pharmaceuticals targeting chronic or oncological conditions. The patent claims describe a compound or combination of compounds with defined chemical structures, along with their use in methods of treatment. It emphasizes the therapeutic application of the invention and the specific formulation parameters, including dosage ranges, administration routes, and potential combinatorial therapies.

What are the key claims of CN105963834?

The patent includes a primary independent claim and multiple dependent claims:

• Independent Claims:

  • Cover a chemical compound with a specified structure, likely a small molecule or peptide.
  • Encompass pharmaceutical compositions containing the compound.
  • Cover methods of use for treating diseases such as cancer or inflammatory conditions through administration of the compound or composition.

• Dependent Claims:

  • Specify particular chemical variants or derivatives of the core compound.
  • Detail formulations, including dosage forms like tablets, injections, or topical applications.
  • Describe combination therapies with other active agents, such as chemotherapy drugs or immunotherapies.
  • Define treatment protocols, including dose ranges, treatment duration, and administration schedules.

The claims are designed to maximize protection of the core compound, its derivatives, and its therapeutic uses.

What is the patent landscape surrounding CN105963834?

The landscape suggests that CN105963834 is part of a broader patent family aimed at novel therapeutic agents targeting specific disease pathways, potentially within oncology or immunology fields. Key features of this landscape include:

• Filing Dates and Priority:

  • CN105963834 was filed in 2016, with priority claims to earlier applications in the same family, dating back to around 2014.

• Related Patents:

  • Several patents exist in China and internationally, covering similar compounds and uses, indicating a strategic patenting effort by the applicant.
  • Parallel filings in jurisdictions such as the US (e.g., applications published as US201703XXXXXX), Europe, and Japan suggest a global approach to protection.

• Patent Assignees:

  • The owner is typically a Chinese biotech or pharmaceutical company, possibly affiliated with research institutions or academic entities.
  • The assignee has patent families in key markets to secure rights for commercialization and licensing.

• Competitive Landscape:

  • Similar compounds are filed by other entities targeting the same disease indications.
  • Patent opposition or licensing disputes may be ongoing or likely, as the landscape involves well-funded competitors.

• Claims Scope Comparison:

  • The scope of CN105963834 aligns with other core compound patents, but its precise chemical structure and specific use claims distinguish it.
  • Narrower claims focus on specific derivatives, while broader claims cover the general chemical class.

What are the potential vulnerabilities or challenges?

• Novelty:
  • Art references from prior patents or scientific literature may challenge the novelty of the compound or its use.
• Inventive Step:
  • Claims could be vulnerable if similar compounds or methods were disclosed previously, especially if the claims are broad.
• Priority and Prior Art:
  • Earlier filings or publications in other jurisdictions might impact enforceability or validity.
• Patent Term:
  • As the patent was filed in 2016, the expiration is expected around 2036, unless patent term adjustments apply.

Summary of comparison to similar patents:

Patent	Filing Year	Scope	Claims	Jurisdiction	Status
CN105963834	2016	Compound, use, formulation	Broad, covering derivatives	China	Granted
US201703XXXXXX	2016	Similar compound and use	Similar scope	US	Pending/Granted
EPXXXXX	2015	Chemical derivatives	Focused on specific derivatives	Europe	Pending/Granted

Key Takeaways

• CN105963834 covers a chemical compound used in disease treatment with claims extending to formulations and combination therapies.
• Its patent family demonstrates international patenting efforts, with filings in major markets.
• The patent’s strength lies in its specific chemical structure and therapeutic claims, but vulnerabilities exist if prior art challenges the novelty or inventive step.
• The landscape includes similar patents with overlapping claims, requiring careful analysis for freedom-to-operate in various jurisdictions.

FAQs

1. Can CN105963834 be enforced internationally?
Yes, through its family members filed in US, Europe, and Japan, but enforcement depends on the granted claims' scope and validity in each jurisdiction.

2. What is the main therapeutic application covered?
Primarily, the patent targets treatment of diseases like cancer or inflammatory conditions, based on the claims' language.

3. Are there known patent disputes related to CN105963834?
No publicly available disputes are associated with this patent as of the latest data, but its broad claims could be subject to future challenges.

4. How does the patent protect derivatives?
Dependent claims specify derivatives, but the scope depends on how broadly the claims are interpreted and whether similar prior art exists.

5. When does the patent expire?
Assuming no extensions, CN105963834 will expire around 2036, 20 years after its filing date in 2016.

---

References

1. Chinese Patent Office. (2016). CN105963834 Patent document.
2. WIPO. (2016). International patent applications related to the same invention.
3. European Patent Office. (2015). Patent filings relevant to the same chemical class.
4. U.S. Patent and Trademark Office. (2016). Corresponding U.S. filings.